22:24

Trace Metal Analysis in APIs by Inductively Coupled Plasma - Mass Spectrometry (ICP-MS)

01:00:26

Process Development Strategies to Deliver Robust Manufacturing Processes

47:53

Expanding Indications Under Open INDs - Regulatory and Product Development Strategies

49:27

Analytical Strategies from Early Development to Validation

08:34

Impurity Control During API Development

07:51

Wet-Mill Micronization in API Development

01:13

Regis Technologies 2nd Edition Chiral Handbook

00:56

Reflect Polysaccharide Columns

08:29

Immobilized Artificial Membrane Columns (IAM); An Advanced Tool for Drug Discovery

03:03

Technical Chromatography Resources from Regis Technologies

08:14

Solid State Chemistry Requirements Throughout CMC Development

01:00:22

Strategies for IND Filing Success

09:11

qNMR: A Powerful and Affordable Tool for Purity/Potency Determination

10:56

Solid Form Selection in the Pharmaceutical Industry: Polymorph Screening (Chapter 2 of 5)

12:10

Solid Form Selection in the Pharmaceutical Industry: Importance in the Drug Development Process

13:44

Solid Form Selection in the Pharmaceutical Industry: Solid Form Characterization Techniques (3 of 5)

15:25

Solid Form Selection in the Pharmaceutical Industry: Late-Appearing and Chiral Polymorphs

01:09:38

Solid Form Selection in the Pharmaceutical Industry (full length seminar)

16:36

Solid Form Selection in the Pharmaceutical Industry: Nucleation and Q&A (Chapter 5 of 5)

01:03:08

Speeding Drug Development through Impurity Control Strategies

01:43

Regis Launches its New Line of Achiral SFC Columns

41:56

Understanding Data Integrity (Full Seminar)

12:01

Understanding Data Integrity Part IV: FDA Warning Letter Examples and Q&A

05:32

Understanding Data Integrity Part II: The ALCOA Principle

16:55

Understanding Data Integrity Part III: Data Integrity Definitions

07:28

Understanding Data Integrity Part I: Introduction to Global Data Integrity

01:01:59

Advancing Chiral Separations

03:13

Podcast: The Importance of a Project Manager When Outsourcing

02:25

Whelk-O 1

02:09

Illinois Family Business of the Year Award 2017: Regis Technologies

18:27

Myths and Urban Legends in Drug Development Part II: Pre Clinical Myths

13:49

Myths and Urban Legends in Drug Development Part IV: Regulatory Myths

09:40

Myths and Urban Legends in Drug Development Part V: Clinical Myths

05:59

Myths and Urban Legends in Drug Development Part III: CMC Myths

05:48

Myths and Urban Legends in Drug Development Part VI: Project Management Myths

12:34

Myths and Urban Legends in Drug Development: Lessons Learned for Small Biotech Companies Part I

08:05

Metrics: The Balance of Performance & Compliance Part II: Quality in Pharma

14:31

FDA 505(b)(2) Applications Seminar Part VIII: Q&A and Discussion of 505(b)(2) Applications

13:04

FDA 505(b)(2) Applications Seminar Part VII: Case Studies on 505(b)(2) Applications

05:32

FDA 505(b)(2) Applications Seminar Part VI: Recent Statistics on 505(b)(2) NDAs

13:43

FDA 505(b)(2) Applications Seminar Part V: Quiz Time Can you identify a (b)(2) Application?

08:31

FDA 505(b)(2) Applications Seminar Part IV: The Thin Line between a 505(j) and 505(b)(2)

06:13

FDA 505(b)(2) Applications Seminar Part III: Developing a 505(b)(2) Application

09:30

FDA 505(b)(2) Applications Seminar Part II: The Regulatory Pathway

08:00

FDA 505(b)(2) Applications Seminar Part I: Where does a 505(b)(2) fit?

01:01:39

Success Factors in Your IND Filing

10:58

Metrics: The Balance of Performance & Compliance Part III: Process Capability

04:33

Metrics: The Balance of Performance & Compliance Part IV: Continuous Improvement

20:03

Metrics: The Balance of Performance & Compliance Part VI: Conclusion & Discussion

08:52

Metrics: The Balance of Performance & Compliance Part V: Continuous Improvement

06:22

Metrics: The Balance of Performance & Compliance Part I: Introduction

36:32

Forced Degradation: Breaking It Down by Paul Wrezel Ph.D. (Full Version)

06:26

Forced Degradation Part VI: Conclusions & Audience Q&A

11:04

Forced Degradation Part V: Design, Experiments, & Data

04:17

Forced Degradation Part IV: Guidelines & Documentation

02:57

Forced Degradation Part III: Suspensions vs Solution & Co-Solvents

06:37

Forced Degradation Part II: Stress Treatments

07:05

Forced Degradation Part I: Introduction & Strategy

10:37

Structure Elucidation of Impurities in Drug Substances by 2D NMR Part V: Conclusions and Q&A

05:58

Structure Elucidation of Impurities by 2D NMR Part IV: Compound C Structure Elucidation